APhA withholds endorsement of ACIP Adult Immunization Schedule
WASHINGTON, June 9, 2025 /PRNewswire/ -- APhA is the only pharmacy representative among several professional organizations that reviews and evaluates the ACIP Adult Immunization Schedule annually. Recently, there have been several updates to the COVID-19 vaccine recommendations made by the Department of Health & Human Services (HHS) and the Centers for Disease Control and Prevention (CDC). These changes include removing the recommendation for people who are pregnant to receive the COVID-19 vaccine.
Studies have shown that people who are pregnant or were recently pregnant are:
More likely to get very sick from COVID-19 compared to those who are not.
More likely to need hospitalization, intensive care, or the use of a ventilator or special equipment to breathe if they do get sick from COVID-19.
At increased risk of complications that can affect pregnancy and the baby, including preterm birth or stillbirth.
COVID-19 vaccination during pregnancy has been proven safe and effective. Additionally, this vaccine is not associated with any fertility issues in either women or men.
APhA's stance is that pregnancy is a high-risk condition; therefore, people who are pregnant should be recommended to receive the COVID-19 vaccine. The May 2025 updates to the COVID-19 vaccine recommendations do not appear to be based on the scientific evidence provided over the past few years.
Considering this recent change, APhA has decided to withhold endorsing the current ACIP Adult Immunization Schedule issued on May 28, 2025. This decision was proposed by a group of APhA members who are immunization subject matter experts and approved by the APhA Board of Trustees.
APhA requests, and is hopeful, that future updates of the Adult Immunization Schedule be based on scientific evidence and would reconsider its endorsement upon the schedule being discussed and recommended by ACIP.
View original content to download multimedia:https://www.prnewswire.com/news-releases/apha-withholds-endorsement-of-acip-adult-immunization-schedule-302476857.html
SOURCE American Pharmacists Association
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
RFK Jr. Is Barely Even Pretending Anymore
The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here. When Robert F. Kennedy Jr. accepted his new position as health secretary, he made a big show of distancing himself from his past life. 'News reports have claimed that I am anti-vaccine or anti-industry,' Kennedy, who has for decades promoted the debunked notion that vaccines cause autism and has baselessly sown doubt over the ability of the U.S. government to vet shots, said at his confirmation hearing in January. 'I am neither. I am pro-safety.' But for all Kennedy's talk, this week, he did exactly what a person would do if they were trying to undermine the scientific consensus on vaccination in the United States. He abruptly dismissed the entire expert committee that advises the CDC on its nationwide vaccine recommendations—and began to fill the roster with like-minded people ready to cast doubt on the benefits of vaccination. Like Kennedy, few of these new appointees to the Advisory Committee on Immunization Practice, or ACIP, have openly embraced the notion that they are anti-vaccine. But among them are individuals who have spoken out against COVID vaccines and policies, claimed vaccine injuries for their own children, and falsely linked COVID shots to deaths—or even baselessly accused those vaccines of 'causing a form of acquired immunity deficiency syndrome.' In January, I wrote that remaking the committee in exactly this way would be an especially harmful blow to Americans' health: Perhaps more than any other body of experts in the U.S., ACIP guides the nation's future preparedness against infectious disease. By appointing a committee that is poised to legitimize more of his own radical views, Kennedy is giving his skewed version of scientific reality the government's imprimatur. Whether he will admit to it or not, he is serving the most core goal of the anti-vaccine movement—eroding access to, and trust in, immunization. In an emailed statement, Health and Human Services Press Secretary Emily G. Hilliard reiterated that 'Secretary Kennedy is not anti-vaccine—he is pro-safety, pro-transparency, and pro-accountability,' and added that his 'evidence-based approach puts accountability and radical transparency first, which will restore trust in our public health system.' (Kennedy, notably, promised Senator Bill Cassidy during his confirmation process that he would maintain ACIP, as Cassidy put it, 'without changes.') Since the 1960s, ACIP has lent government policy on vaccines the clout of scientific evidence. Its mandate is to convene experts across fields such as infectious disease, immunology, pediatrics, vaccinology, and public health to carefully vet the data on immunizations, weigh their risks and benefits, and vote on recommendations that guide the public on how to use them—who should get vaccines, and when. Those guidelines are then passed to the CDC director, who—with only the rarest of exceptions—accepts that advice wholesale. 'These recommendations are what states look to, what providers look to,' Rupali Limaye, an expert in vaccine behavior at the Johns Hopkins Bloomberg School of Public Health, told me. Medicare, for instance, is required to fully cover the vaccines that ACIP recommends; ACIP also determines which vaccines are covered by the Vaccines for Children Program, which provides free vaccines for children whose families cannot afford them. The experts who serve on ACIP have the opportunity, more than just about any of their scientific peers, to translate their vaccine rhetoric into reality. So far, Kennedy has dismissed the 17 people who were serving on ACIP, and filled eight of the newly open slots. Most of the new nominees have an obvious bone to pick with at least some vaccines, especially COVID shots, and have publicly advocated for limiting their use. Among the new members, for instance, is Robert Malone, a controversial physician who has spoken at anti-vaccine events, where he has denounced COVID vaccines and, without evidence, suggested that they can worsen coronavirus infections. Another appointee is Vicky Pebsworth, who serves on the board of the National Vaccine Information Center, an anti-vaccine nonprofit previously known as Dissatisfied Parents Together. A third, Retsef Levi, a health-care-management expert, called for the administration of COVID vaccines to be halted in 2023, and has questioned the shots' safety, despite a large body of evidence from clinical trials supporting their continued use. Overall, 'this is not a list that would increase confidence in vaccine decisions,' Dorit Reiss, a vaccine-policy expert at UC San Francisco, told me. (None of these new ACIP members returned a request for comment.) The next ACIP meeting is scheduled for the end of this month—and the agenda includes discussion about anthrax vaccines, chikungunya vaccines, COVID-19 vaccines, cytomegalovirus vaccine, the human-papillomavirus vaccine, influenza vaccines, the Lyme-disease vaccine, meningococcal vaccines, pneumococcal vaccines, and RSV vaccines. That's a big slate of topics for a brand-new panel of members, Paul Offit, a pediatrician and a vaccine expert who has previously served on ACIP, told me: Depending on how the meeting is structured, and on the input from CDC scientists, these new committee members could substantially alter the guidelines on several immunizations—perhaps so much so that certain shots could stop being recommended to certain groups of Americans. Based on the composition of the committee so far, Offit predicts that the new ACIP will eventually push the CDC away from full-throated endorsement of many of these vaccines. Even subtle changes in the wording of CDC recommendations—a should swapped for a may—can have big ripple effects, Limaye told me. Insurers, for instance, may be more reluctant to cover vaccines that are not actively endorsed by the CDC; some states—especially those in which vaccines have become a political battleground—may stop mandating those types of shots. If the CDC softens its recommendations, 'we will likely see more partisan divides' in who opts for protection nationwide, Jason Schwartz, a vaccine-policy expert at Yale, told me. Pharmaceutical companies may, in turn, cut down production of vaccines that don't have full CDC backing, perpetuating a cycle of reduced availability and reduced enthusiasm. And primary-care physicians, who look to the CDC's vaccination schedule as an essential reference, may shift the language they use to describe childhood shots, nudging more parents to simply opt out. Historically, medical and public-health associations, such as the American Academy of Pediatrics, have aligned their vaccine recommendations with ACIP's—because those recommendations were all driven by scientific evidence. Now, though, scientific consensus and government position are beginning to diverge: Multiple groups of physicians, scientists, and public-health scholars have issued statements condemning the vaccine decisions of Kennedy and his allies; a number of prominent scientists have now banded together to form a kind of alt-ACIP, dubbing themselves the Vaccine Integrity Project. As the views of fringe vaccine groups become the government's stance, Americans may soon have to choose between following the science and following what their nation's leaders say. Identifying as 'anti-vaccine' has historically been taboo: In a nation where most people remain largely in favor of shots, the term is pejorative, an open acknowledgment that one's views lie outside of the norm. But the more vaccine resistance infiltrates HHS and its advisers, the more what's considered normal may shift toward Kennedy's own views on vaccines; ACIP's reputation for evidence-backed thinking could even gild those views with scientific legitimacy. Assembling one's own team of friendly experts is an especially effective way to sanewash extremism, Reiss told me, and to overturn the system through what appear to be normal channels. If the nation's most prominent group of vaccine advisers bends toward anti-vaccine, the term loses its extremist edge—and the scientists who argue, based on sound data, that vaccines are safe and effective risk being labeled anti-government. Article originally published at The Atlantic
Yahoo
an hour ago
- Yahoo
Overdose deaths decrease nationwide, and here in the Upstate
SPARTANBURG COUNTY, S.C. (WSPA) – According to the Center for Disease Control (CDC), overdose deaths have decreased nationwide by almost 27% in the past year, and are projected to reach their lowest level since 2019. 'You realize you have a problem, you know true leadership is dealing with the problem and then putting the plan in place, and I believe that's probably what's happening nationwide,' said Spartanburg Co. coroner Rusty Clevenger. Clevenger's data showed overdose deaths in Spartanburg Co. skyrocketed during Covid. He said it was then that he and state officials knew they not only needed to track the deaths, but exactly where these drugs were coming from and which ones were the cause. 'We had to figure out where the hotspots were at so we could put you know, measures in place to try, whether it be education or whatever, and it seems to be working as well,' he said. Data showed Spartanburg County saw a marked decrease in overdose deaths in 2024. 'The numbers are holding steady about last year's levels, maybe a little bit less right now,' Clevenger explained. However Keith Blanton, the Pastor and Superintendent at Faith Home, a non-profit Christian recovery center, said beds in their facilities across the Upstate stay full. He told us between their four locations, there are 135 beds. 'I think more people are getting help,' said Blanton. 'I just do. I think that you know, Narcan is a good thing. It saves people's lives and as long as they're alive, you know there's a chance.' Blanton said thanks to the coroner's office and law enforcement agencies tracking 'hotspots' and providing education, drugs no longer have to be the end of every user's story. 'It's tough,' Blanton said. 'It's tough at first especially, but it gets easier, and it gets better. But if I had one thing to say, you do not have to live that way, there's a way out if you want out.' Blanton told 7NEWS over the years that the people they serve have become significantly younger. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that it will present multiple clinical study results of mazdutide at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago, U.S. from June 20 -23. Innovent will orally present the first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1). In addition, multiple exploratory MoA analyses of mazdutide as well as preclinical study of IBI3030 (PCSK9-GGG antibody-peptide-conjugate) will be showcased in poster presentations. Details are listed below： Title: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)Abstract #：306-OR Presentation Form: Oral presentationTime: 2025 June 23, 14:15 PM – 14:30 PM（CST）Presenter: Dr. Lei Qian, Innovent Biologics Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical studyAbstract #：1886-LBPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Dr. Decheng Ren, Innovent Biologics Title: The Dual Glucagon and Glucagon-Like Peptide 1 Receptor Agonist Mazdutide Outbalanced Glucagon-Like Peptide 1 Receptor Agonist Semaglutide Monotherapy in Improving Mice Liver Fat AccumulationAbstract #：777-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Hong, Peking University Third Hospital Title: Effect of Mazdutide on MASH Fibrosis – Targeting the Liver-Gut Axis and MicrobiomeAbstract #：1616-P Presentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Professor Ling Li, Zhongda Hospital Affiliated to Southeast University Title: Mazdutide, a Dual GLP-1R/GCGRR Agonist, Reduces Hyperuricemia by Modulating Energy and Lipid Metabolism and Inhibiting Hepatic Purine MetabolismAbstract #：775-PPresentation Form: Poster presentationTime: 2025 June 22, 12:30 PM – 1:30 PM（CST）Presenter: Professor Hongwei Jiang, The First Affiliated Hospital of Henan University of Science and Technology Dr. Lei Qian, Vice President of Clinical Development of Innovent, stated, "We are honored to orally present the results of mazdutide's first Phase 3 clinical trial in T2D (DREAMS-1) at the ADA Scientific Sessions. We are also delighted to see mazdutide's mechanism exploration studies featured extensively at the conference. The growing body of medical evidence will further validate mazdutide's differentiated profile as a next-generation GCG/GLP-1 dual receptor agonist, in particularly in liver fat and serum urine reduction. Moreover, in the field of cardiovascular and metabolic diseases, Innovent is dedicated to developing next-generation innovative therapies, including IBI3030（PCSK9-GGG）with novel modality and MoA, to meaningfully improve outcomes for more patients worldwide." About Mazdutide (IBI362) Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of OXM3 (also known as mazdutide), a GLP-1R and GCGR dual agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, mazdutide may offer additional benefits beyond those of GLP-1 receptor agonists—such as promoting insulin secretion, lowering blood glucose and reducing body weight—by also activating the glucagon receptor to increase energy expenditure and improve hepatic fat metabolism. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies. It has also shown benefits in reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes, and liver fat content, as well as improving insulin sensitivity. Currently, Mazdutide has two NDAs accepted for review by NMPA, including: Long-term weight management in adults with obesity or overweight. Glycemic control in adults with type 2 diabetes (T2D). Mazdutide is currently being evaluated in six Phase 3 clinical studies, including: GLORY-1: A Phase 3 trial in Chinese participants with overweight or obesity. GLORY-2: A Phase 3 trial in Chinese participants with moderate-to-severe obesity. GLORY-3: A Phase 3 trial comparing Mazdutide and Semaglutide in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). DREAMS-1: A Phase 3 trial in treatment-naïve Chinese participants with T2D. DREAMS-2: A Phase 3 trial comparing Mazdutide and Dulaglutide in Chinese T2D participants with inadequate glycemic control on oral antidiabetic drugs. DREAMS-3: A Phase 3 trial comparing Mazdutide and Semaglutide in Chinese participants with T2D and obesity. Among these, GLORY-1, DREAMS-1, and DREAMS-2 have already met their primary endpoints and others are currently ongoing. In addition, several new clinical studies of mazdutide are planned, including: A Phase 3 trial in adolescents with obesity. New studies in metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Forward-looking statement This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
